Justin Gover
December 18, 2017|Neurology Reviews
Justin Gover, Chief Executive Officer of Greenwich Biosciences, discusses the FDA's planned review of Epidiolex, a formulation of cannabidiol, for the treatment of Dravet syndrome and Lennox-Gastaut syndrome.